Posted in | News | Gold

First Gold Exploration Announces Drilling Results of the Rose Project

First Gold Exploration Inc. (TSX VENTURE:EFG) (FRANKFURT:F12) (OTCQX:FGEXF) has reported the most recent drill results for the Lac Pivert/Rose project.

All the holes intersected mineralization and extended the mineralized zone at Rose eastward.

Drilling continues, with the drill now working on the Hydro, Pivert and JR showings. To date, three holes have been drilled on the Hydro showing and twelve on the JR showing. Drilling has returned numerous mineralized intersections. The details and assay results for these intersections will be disclosed over the coming weeks as they are received.

InnovExplo was hired in June to prepare a 43-101 report on the Pivert/Rose property, as well as a resource estimate for the project.

The 43-101 property report can be found on Sedar, and the resource estimate is expected before the end of the year. The work is progressing well to date, and no delays are expected. The Company will order a prefeasibility study as soon as it receives the resource estimate.

All the samples were sent for analysis in sealed containers to the Chemex laboratory in Val-d'Or by employees of the Company. Chemex is the laboratory used for analysis of all samples from programs on the Lac Pivert/Rose property. The samples are weighed and identified prior to sample preparation. The samples are crushed to 70% minus 2 mm, then separated and pulverized to 85% passing 75 um. All samples are analyzed using ICP-MS, with full analysis for 47 elements.

Jean-Sebastien Lavallee (OGQ #773), geologist, shareholder, interim president and chief executive officer of the Company and Qualified Person under NI 43-101, has reviewed and approved the technical content of this release.

Source: First Gold Exploration Inc.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.